Concentration of Customers and Suppliers (Details 2) (Research and Development Expenses)	12 Months Ended
Dec. 31, 2011	Dec. 31, 2012 Third party manufacturer Qsymia and STENDRA post-approval studies CRO	Dec. 31, 2010 Third party manufacturer Qsymia Phase 3 studies CRO	Dec. 31, 2010 Third party manufacturer Avanafil Phase 3 studies CRO	Dec. 31, 2010 Third party manufacturer Clinical supplies and formulation work
Concentration of Suppliers
Threshold for disclosure as a percentage of total research and development expenses	10.00%
Expenses accounted for ten percent or more of total research and development expenses (as a percent)		13.00%	20.00%	20.00%	12.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Name:	us-gaap_ConcentrationRiskPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant